C. Ruschil

发表

The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model

K. Fujihara, B. Hemmer, C. Geis, 2015, Experimental Neurology.

Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid – no clear evidence of positive disease modifying effects

U. Ziemann, M. Krumbholz, C. Ruschil, 2021, Neurological Research and Practice.

Comparative multi-OMICS single cell atlas of five COVID-19 (rAdVV and mRNA) vaccines describe unique and distinct mechanisms of action

S. Nahnsen, C. Ruschil, P. Kremsner, 2022, bioRxiv.

Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses

S. Nahnsen, U. Ziemann, B. Hemmer, 2020, bioRxiv.

Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry

F. Paul, P. Schwenkreis, F. Zipp, 2020, Drug Safety.

Differentiation Between Guillain–Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis—a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements

H. Axer, C. Ruschil, A. Grimm, 2019, Neurotherapeutics.

Validating Alzheimer's disease micro RNAs using next-generation sequencing

D. Berg, C. Ruschil, J. Haas, 2016, Alzheimer's & Dementia.

Featured Article Validating Alzheimer's disease micro RNAs using next-generation sequencing

D. Berg, C. Ruschil, J. Haas, 2016 .

Next Generation Sequencing of Cerebrospinal Fluid B Cell Repertoires in Multiple Sclerosis and Other Neuro-Inflammatory Diseases—A Comprehensive Review

C. Ruschil, G. Gabernet, M. Kowarik, 2021, Diagnostics.

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4

R. Schüle, M. Krumbholz, C. Ruschil, 2022, International journal of molecular sciences.

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

Adam L. Comer, Robert G. Miller, S. Demeret, 2023, The Lancet Neurology.

Clinical-Radiological Mismatch in Multiple Sclerosis Patients during Acute Relapse: Discrepancy between Clinical Symptoms and Active, Topographically Fitting MRI Lesions

B. Bender, C. Ruschil, T. Lindig, 2023, Journal of clinical medicine.

Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab

U. Ziemann, M. Krumbholz, B. Hemmer, 2020, PloS one.

Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients

S. Nahnsen, C. Ruschil, G. Gabernet, 2023, Frontiers in Immunology.

Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy

C. Ruschil, F. Bischof, Evelyn Dubois, 2015, Neurology: Neuroimmunology & Neuroinflammation.

Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation

C. Ruschil, R. F. Sîrbulescu, M. C. Kowarik, 2024, Frontiers in cellular neuroscience.

Validating Alzheimer's disease micro RNAs using next-generation sequencing

D. Berg, C. Ruschil, J. Haas, 2016, Alzheimer's & Dementia.

In-depth analysis of serum antibodies against Epstein-Barr virus lifecycle proteins, and EBNA1, ANO2, GlialCAM and CRYAB peptides in patients with multiple sclerosis

C. Ruschil, M. Kowarik, U. Ziemann, 2024, Frontiers in Immunology.